Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.
about
Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature reviewCurrent therapies for lowering lipoprotein (a)Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selectionHuman Genetics and the Causal Role of Lipoprotein(a) for Various DiseasesGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Relook at lipoprotein (A): independent risk factor of coronary artery disease in north Indian population.Low lipoprotein(a) concentration is associated with cancer and all-cause deaths: a population-based cohort study (the JMS cohort study).Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levelsLipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe studyClinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular diseaseA Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis.Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemiaRelationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).Development of Antisense Drugs for Dyslipidemia.The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia.Lipoprotein(a): resurrected by genetics.Update on lipoprotein(a) as a cardiovascular risk factor and mediator.Screening for and management of elevated Lp(a).Critical review of non-statin treatments for dyslipoproteinemia.Lipoprotein(a) as a therapeutic target in cardiovascular disease.The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory anginaTargeting lipoprotein (a): an evolving therapeutic landscape.Lipoprotein apheresis to treat elevated lipoprotein (a)Hyperlipoproteinaemia(a) - apheresis and emerging therapies.Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.Lipoprotein(a)-clinical aspects and future challengesPrimary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease.Lipoprotein(a): A Lipoprotein Whose Time Has Come.Lipoprotein(a): the revenant.Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment.Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions.Exercise electrocardiogram testing in two brothers with different outcome - a case study exercise testing in master cyclists.HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias.[Update dyslipidemia].Lipoprotein apheresis in isolated hyperlipoproteinemia(a): a validated treatment or an illusion of validity?
P2860
Q26771862-3DF4134C-B908-443C-BC04-F410094AB49BQ26830297-86DE4728-2321-41AE-8CDE-BBBDB83F0E75Q28078664-9B000EAD-FC9F-4E17-9F0C-7513F08FCB4DQ28079294-19C9C1F2-00EE-4E4E-9685-24439675D578Q30276550-4F0DE659-7C79-496B-BED5-C494ABC40740Q34002189-03EDFEC1-7E92-47DA-8AA4-38C1BC6467CDQ34224722-33B792FD-3C0B-41F7-90AA-78FB8E6CE150Q34571030-5CDD45E6-53A1-411F-A6A0-E3E27F0C0120Q35182551-E89D0522-B141-4849-8B76-D3F9AB181962Q35182567-7E560E93-E706-418D-A24A-FC6BFCE438F8Q35182640-2A922FBA-7F0B-4BDD-A7E4-1E57C4AB874FQ36469043-C9D96125-C142-46AD-9981-80B1B4B7BD3BQ36520326-16B2846D-7FE8-4CF5-B534-1F60EC0B3589Q37239481-56821D67-295A-4E9D-B509-3B7A6DFDB12FQ37387192-C1DCEE78-9304-43F6-A0EE-39B8BE2A5030Q37703258-13AE007B-7B5D-48E4-AD4E-A8AB90B772EDQ37965588-5721F289-4B22-463A-A284-5AB0BD43C79AQ38045424-D257FDAD-3420-4743-87EF-4CE54AF3C9D3Q38132701-205B9FAC-5484-4B51-B419-00214DB4D570Q38140754-253E8A57-1B88-4EF1-B56B-DE80C5DC47A9Q38186099-46FF286B-897C-4313-8A1E-2A85272085A4Q38213476-1C8EBD94-63B8-4589-8765-FDEDE1072D5DQ38233052-E32197C0-5441-486C-BCCD-D7BB8C90C33AQ38367355-C8F1230A-04E2-4F54-B81F-A120BBE09716Q38738379-E5104121-B2F8-4819-8471-696365E62497Q38968510-E07EE941-94FF-4E58-8AF3-8A944F6EA27CQ38985774-12B1067D-8BA5-4692-A132-CB2EAA754938Q39033744-48B7579F-EE95-42A6-A751-21E9A9D5D301Q39148923-6948A1E3-6CF6-457B-9146-C4AB4F04BB6BQ39284105-3515CEE4-ADB2-4E21-A56B-1A8224E817CDQ39308941-6E035A57-CB81-405E-8467-C00B942E3982Q40280257-2655BDD8-DEFB-4C01-8E29-90FEB73A3FE5Q40707724-BB205E2C-0EF8-4350-A338-EA8CBC8FECA5Q40757066-EDA6ADBE-74CE-4A41-AD9B-733931D34D5AQ41393113-B2FD4113-15D2-4E4C-8B24-56244A467F43Q42396853-E51E5381-6F60-4C2C-A038-8C85E4D5D629Q43188537-7E4C1F02-4771-4C31-8B83-BDF71FDDF508Q43188572-B6DDFC1B-C6D4-48DC-8FE7-FB7F9E65AC73Q43491912-3D1061EC-9958-428F-ADB1-B6DCC0377563Q45101365-8D28ADFC-DBE4-49B5-BC9C-A15B0C2D60D1
P2860
Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Longitudinal cohort study on t ...... ent to reduce high lipoprotein
@nl
Longitudinal cohort study on t ...... major adverse coronary events.
@ast
Longitudinal cohort study on t ...... major adverse coronary events.
@en
type
label
Longitudinal cohort study on t ...... ent to reduce high lipoprotein
@nl
Longitudinal cohort study on t ...... major adverse coronary events.
@ast
Longitudinal cohort study on t ...... major adverse coronary events.
@en
prefLabel
Longitudinal cohort study on t ...... ent to reduce high lipoprotein
@nl
Longitudinal cohort study on t ...... major adverse coronary events.
@ast
Longitudinal cohort study on t ...... major adverse coronary events.
@en
P2093
P2860
P356
P1476
Longitudinal cohort study on t ...... major adverse coronary events.
@en
P2093
Beate R Jaeger
Carlos A Labarrere
Dietrich Seidel
Dorothea Nagel
Eberhard Roeseler
Franz Heigl
Gerd Utermann
Group of Clinical Investigators
Klaus Parhofer
P2860
P304
P356
10.1038/NCPCARDIO1456
P577
2009-03-01T00:00:00Z